Document Detail


Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients.
MedLine Citation:
PMID:  21985946     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To determine whether human papillomavirus (HPV) DNA can be detected in the plasma of patients with HPV-positive oropharyngeal carcinoma (OPC) and to monitor its temporal change during radiotherapy.
METHODS AND MATERIALS: We used polymerase chain reaction to detect HPV DNA in the culture media of HPV-positive SCC90 and VU147T cells and the plasma of SCC90 and HeLa tumor-bearing mice, non-tumor-bearing controls, and those with HPV-negative tumors. We used real-time quantitative polymerase chain reaction to quantify the plasma HPV DNA in 40 HPV-positive OPC, 24 HPV-negative head-and-neck cancer patients and 10 non-cancer volunteers. The tumor HPV status was confirmed by p16(INK4a) staining and HPV16/18 polymerase chain reaction or HPV in situ hybridization. A total of 14 patients had serial plasma samples for HPV DNA quantification during radiotherapy.
RESULTS: HPV DNA was detectable in the plasma samples of SCC90- and HeLa-bearing mice but not in the controls. It was detected in 65% of the pretreatment plasma samples from HPV-positive OPC patients using E6/7 quantitative polymerase chain reaction. None of the HPV-negative head-and-neck cancer patients or non-cancer controls had detectable HPV DNA. The pretreatment plasma HPV DNA copy number correlated significantly with the nodal metabolic tumor volume (assessed using (18)F-deoxyglucose positron emission tomography). The serial measurements in 14 patients showed a rapid decline in HPV DNA that had become undetectable at radiotherapy completion. In 3 patients, the HPV DNA level had increased to a discernable level at metastasis.
CONCLUSIONS: Xenograft studies indicated that plasma HPV DNA is released from HPV-positive tumors. Circulating HPV DNA was detectable in most HPV-positive OPC patients. Thus, plasma HPV DNA might be a valuable tool for identifying relapse.
Authors:
Hongbin Cao; Alice Banh; Shirley Kwok; Xiaoli Shi; Simon Wu; Trevor Krakow; Brian Khong; Brindha Bavan; Rajeev Bala; Benjamin A Pinsky; Dimitrios Colevas; Nader Pourmand; Albert C Koong; Christina S Kong; Quynh-Thu Le
Related Documents :
22265216 - Persistently bound ku at dna ends attenuates dna end resection and homologous recombina...
9546446 - Idiopathic scoliosis in twins studied by dna fingerprinting: the incidence and type of ...
22155186 - Dna topoisomerase iiα inhibitory and anti-hiv-1 flavones from leaves and twigs of garde...
12669796 - Aflp-based assessment of genetic diversity among nine alfalfa germplasms using bulk dna...
457746 - Mechanisms of transcription in nucleoli of amphibian oocytes as visualized by high-reso...
10502496 - Dna profiling reveals remarkably low genetic variability in a herd of sla homozygous pigs.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-10-08
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  82     ISSN:  1879-355X     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-01-30     Completed Date:  2012-03-15     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e351-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Animals
Carcinoma, Squamous Cell / blood*,  chemistry,  therapy,  virology
Chemoradiotherapy
Cyclin-Dependent Kinase Inhibitor p16 / analysis*
DNA, Viral / blood*,  isolation & purification
Gene Dosage
Genetic Markers / genetics
Human papillomavirus 16 / genetics*
Human papillomavirus 18 / genetics*
Humans
Male
Mice
Mice, SCID
Middle Aged
Oropharyngeal Neoplasms / blood*,  chemistry,  pathology,  therapy,  virology
Real-Time Polymerase Chain Reaction
Tumor Burden
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
1 R01 CA118582-05/CA/NCI NIH HHS; R01 CA118582/CA/NCI NIH HHS; R01 CA118582-04S1/CA/NCI NIH HHS; R01 CA118582-05/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Cyclin-Dependent Kinase Inhibitor p16; 0/DNA, Viral; 0/Genetic Markers
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on...
Next Document:  Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: l...